News

News & Events

Stay informed with Atriva Therapeutics

Atriva Therapeutics kann dank Fördermitteln COVID-19-Medikament schneller entwickeln
Das biopharmazeutische Unternehmen Atriva Therapeutics GmbH, ein Vorreiter bei der Entwicklung von …
Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding
Atriva Therapeutics GmbH, a company that is pioneering the development of therapies …
Atriva Therapeutics Doses First Patient in Phase II RESPIRE trial in COVID-19
Atriva Therapeutics GmbH, a biopharmaceutical company that is pioneering the development of …
Atriva Therapeutics Announces Changes to Management in COVID-19
Atriva Therapeutics GmbH, a biopharmaceutical company that is pioneering the development of …

News Overview

Title
Atriva Therapeutics kann dank Fördermitteln COVID-19-Medikament schneller entwickelnDas biopharmazeutische Unternehmen Atriva Therapeutics GmbH, ein Vorreiter bei der Entwicklung von Therapien zur Behandlung von viralen Infektionen, hat sich Fördermittel des Bundes gesichert.2021-04-21Press Releasepublish
Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal FundingAtriva Therapeutics GmbH, a company that is pioneering the development of therapies for the treatment of viral infections, has secured up to €11.4 million in federal funding.2021-04-21Press Releasepublish
Atriva Therapeutics Doses First Patient in Phase II RESPIRE trial in COVID-19Atriva Therapeutics GmbH, a biopharmaceutical company that is pioneering the development of host-targeting antiviral therapies, announced today that the first patient was enrolled in its Phase II RESPIRE1 trial in COVID-19.2021-04-13Press Releasepublish
Atriva Therapeutics Announces Changes to Management in COVID-19Atriva Therapeutics GmbH, a biopharmaceutical company that is pioneering the development of host-targeting antiviral therapies, today announced two changes to its management team.2021-04-13Press Releasepublish
Atriva Therapeutics Announces Changes to Advisory BoardAtriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced changes to its Advisory Board.2021-01-20Press Releasepublish
Atriva Therapeutics obtains approval from German authorities for Phase II trial in COVID-19 patients, led by Charité Clinic in BerlinAtriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced today approval from the German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) to initiate a pivotal Phase II clinical study with ATR-002 to treat hospitalized patients with moderate to severe COVID-19.2021-01-05Press Releasepublish
Initiative BEAT-COV fordert Unterstützung für Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente„Wir können lebenswichtige Medikamente zur Behandlung von COVID-19-Patienten zur Verfügung stellen, aber wir benötigen signifikante Unterstützung bei der Finanzierung der Entwicklungs- und Produktionskosten – jetzt!“ 2020-12-02Press Releasepublish
Germany: EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatmentThe European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses.2020-10-20Press Releasepublish
Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loanAtriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the closing of a € 8.6 million ($ 10.2 million) convertible loan led by Meneldor B.V. and High-Tech Gründerfonds (HTGF), and joined by existing shareholders and new German and international investors.2020-08-11Press Releasepublish
Publication in PNAS unveils molecular pathway required for influenza virus replication with large potential as an antiviral drug targetAtriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the publication of in vitro results by Atriva Co-founder Prof. Stephan Ludwig.2020-06-30Press Releasepublish
Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II StudyAtriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced a clinical strategy to treat patients with moderate to severe COVID-19 who require hospitalization. 2020-05-28Press Releasepublish
Major conferences in San FranciscoAtriva Therapeutics GmbH, a clinical stage biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announces its participation in three upcoming conferences in San Francisco, CA, USA, in January. 2020-01-08Events, Press Releasepublish
Atriva Therapeutics Reports Results of ATR-002 Phase I Clinical TrialAtriva Therapeutics GmbH, a biopharma­ceutical company pioneering the development of host-targeting antiviral therapies, today announced the successful conclusion and top-line results of its Phase I clinical trial for its lead drug candidate ATR-002. 2019-11-08Press Releasepublish
Atriva Therapeutics to present at the BIO-Europe in HamburgAtriva Therapeutics GmbH, a biopharma­ceutical company pioneering the development of host-targeting antiviral therapies, will present at the upcoming 25th Annual International Partnering Conference BIO-Europe®.2019-10-31Events, Press Releasepublish
Atriva Therapeutics takes part in four conferences in the upcoming monthsAtriva Therapeutics takes part in four conferences in the upcoming months.2019-09-03Events, Press Releasepublish
Atriva Therapeutics Receives EU Award for Biomarker ValidationAtriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced that they have received the Biomarker Validation Award as part of the European Interreg Project Codex4SME.2019-07-17Press Releasepublish
Atriva Therapeutics Starts Clinical Development of novel Host-Targeting Antiviral ATR-002 Against InfluenzaAtriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the first dosing of its lead drug candidate ATR-002 in a Phase I clinical trial.2019-05-15Press Releasepublish
Atriva Therapeutics announces first closing of series A financing roundAtriva Therapeutics, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the first closing in its ongoing series A financing round lead by Meneldor and High-Tech Gründerfonds GmbH (HTGF). 2019-01-07Press Releasepublish
Wirtschaftswoche: 1,25 Mio. Euro für den Kampf gegen VirenAtriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced changes to its Advisory Board.2019-01-07Media Coverage, Press Releasepublish
Atriva adds Dr. Christian Wallasch to its executive management team.After successfully passing an important preclinical development milestone for the lead compound ATR-002 in summer 2017, Atriva Therapeutics GmbH adds a seasoned biopharmaceutical executive, Dr. Christian Wallasch as Chief Operating Officer (COO) to its executive management team.2018-11-07Press Releasepublish
Atriva receives seed financing to develop its next generation influenza therapeuticThe next generation of Antiviral Therapies: Led by Stichting Participatie Atriva together with High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received seed financing from Dutch and German private investors.2018-02-07Press Releasepublish